Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 14,746 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pulmonary Clear all

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 17,183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 303
States / cities: Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Anaheim, California • Los Angeles, California • Panama City, Florida + 8 more

Conditions: Lung Cancer
Interventions: ISIS 3521, carboplatin, paclitaxel; Biological · Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 2
States / cities: Carlsbad, California • Cleveland, Ohio

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Chronic Graft Versus Host Disease
Interventions: Fostamatinib, Ruxolitinib; Drug
Lead sponsor: Stefanie Sarantopoulos, MD, PhD.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Extensive-stage Small Cell Lung Cancer
Interventions: BMS-986012, Carboplatin, Etoposide, Nivolumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Birmingham, Alabama • Hackensack, New Jersey • Durham, North Carolina + 4 more

Conditions: Non Small Cell Lung Carcinoma NSCLC
Interventions: Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions: MM-151, MM-121, MM-141, trametinib; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Aurora, Colorado • Sandy Springs, Georgia • Chicago, Illinois + 2 more

Conditions: Pulmonary Infections, Pseudomonas Aeruginosa in Cystic Fibrosis
Interventions: TBM100; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Little Rock, Arkansas • Denver, Colorado • Jacksonville, Florida + 16 more

Conditions: COVID-19, Sars-CoV2
Interventions: Progesterone 100 MG; Drug
Lead sponsor: Sara Ghandehari; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Long COVID
Interventions: Tonabersat, Placebo; Drug
Lead sponsor: Inflammx Therapeutics Inc; Industry
Eligibility: 21 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation, Pseudomonas Aeruginosa Infection
Interventions: Ceftolozane/Tazobactam; Drug
Lead sponsor: Joseph L. Kuti, PharmD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Hartford, Connecticut • Indianapolis, Indiana • Chapel Hill, North Carolina + 1 more

Conditions: Disease Progression
Interventions: De novo tumor tissue biopsy, Research blood draws; Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 17
States / cities: Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 10 more

Conditions: COVID-19, Obesity
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 5,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Non-Small Cell Lung Cancer
Interventions: ABI-007; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma, Asthma in Children, Wheezing, Pediatric Asthma
Interventions: RESP™ Biosensor; Device
Lead sponsor: Strados Labs, Inc.; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 36 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: The Bronx, New York • Charlotte, North Carolina

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone, Pentamidine isethionate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 20
States / cities: Berkeley, California • Harbor City, California • Los Angeles, California + 12 more

Conditions: Asthma
Interventions: Mometasone furoate 220, KoKo Spirometry, Mometasone furoate 440, Oscillometry; Drug · Device
Lead sponsor: California Allergy and Asthma Medical Group, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COVID-19, COVID-19 Testing
Interventions: Motivational interviewing (MI) counseling, Text messages (TMs) and quiz questions (QQs), Peer education, Access to COVID testing; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Non Small Cell Lung Cancer, Lung Cancer Stage 1
Interventions: Liposomal Bupivacaine, Bupivacaine-Epinephrine; Drug
Lead sponsor: Southern Illinois University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Pneumonia
Interventions: chlorhexidine gluconate oral rinse (0.12%), placebo; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
Interventions: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks; Genetic
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2037
U.S. locations: 9
States / cities: Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more

Conditions: Asthma
Interventions: Atuliflapon, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 64
States / cities: Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 52 more

Search by objective public record fields.

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients

Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer

An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Progesterone for the Treatment of COVID-19 in Hospitalized Men

Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)

Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients

Treatment Resistance Following Anti-cancer Therapies

The Impact of the COVID-19 Pandemic on Eating Behavior and Weight Change

Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer

Wearable Auscultation Device Validation in Children

Real World Data on Gi(l)Otrif® Dose Adjustment

A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole

Onset and Duration of Mometasone by Oscillometry and Spirometry

Using MOST to Optimize an Intervention to Increase COVID-19 Testing for Frontline Essential Workers

Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients

Effect of Improved Oral Hygiene to Prevent Pneumonia in Hospitalized Patients

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma